Emergent Biosolutions (EBS) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Emergent Biosolutions (EBS) do?
Emergent Biosolutions Inc (EBS) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Produces vaccines and therapeutics for public health threats including anthrax, smallpox, and chemical attacks. Manufactures biodefense medical countermeasures for government stockpiles and opioid overdose reversal treatments for. It is worth $264.78M on the market and sold $645.80M over the last year.
- Market cap
- $264.78M
- P/E ratio
- None (reported a loss)
- Annual sales
- $645.80M
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Brief updated
- Nov 18, 2026
Brands and businesses behind EBS
- Narcan: Generates revenue by selling over-the-counter naloxone nasal sprays to retail pharmacies and state harm-reduction programs.
- ACAM2000: Earns revenue through federal defense contracts providing smallpox and mpox immunization supplies to national strategic stockpiles.
- BioThrax: Sells anthrax vaccine doses primarily to government defense agencies for military personnel and emergency preparedness stockpiles.
- Cyfendus: Generates revenue from government contracts for next-generation post-exposure anthrax prophylaxis vaccines.
EBS’s flags, in plain English
Each flag is a number from Emergent Biosolutions’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Stupid Cash
Can pay this year's bills 4.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Cheap on Cash Flow
Priced at 1.4 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Insiders Hold
Insiders own 6% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Debt Is Driving
Heavy debt, 164% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about EBS
How big is Emergent Biosolutions?
Emergent Biosolutions’ market cap is $264.78M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $645.80M: what customers paid the company over the last year, before any costs.
What is EBS’s P/E ratio?
EBS has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with EBS?
Revenue depends heavily on procurement contracts from the United States government that expire and require periodic renewals. That is one risk on Emergent Biosolutions’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Emergent Biosolutions’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. EBS’s filings on SEC.gov. The Margin Monkey is research, not advice.
